Vanda (VNDA) Q2 Revenue Rises 4%
Vanda Pharmaceuticals (NASDAQ:VNDA), a pharmaceutical company focused on central nervous system and rare disease treatments, reported financial results for Q2 2025 on July 31, 2025. The most important news was a GAAP net loss of $27.2 million for Q2 2025, driven by sharply higher operating costs. GAAP revenue for Q2 2025 rose 4.0% from the prior year to $52.6 million, but still missed analyst forecasts of $54.77 million for Q2 2025 (GAAP). Overall, the quarter saw robust sales growth for Fanapt®, offset by continued challenges for other key products and substantial increases in research and selling expenses.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Vanda Pharmaceuticals specializes in developing and commercializing therapies for neurological and rare disorders. Its main products include Fanapt®, an antipsychotic for schizophrenia and bipolar I disorder; HETLIOZ®, a treatment for circadian rhythm disorders; and PONVORY®, a therapy for multiple sclerosis.
Source Fool.com
